Opiant Pharmaceuticals (Opiant Pharmaceuticals) LT-Debt-to-Total-Asset : 0.34 (As of Sep. 2022)

View and export this data going back to 2007. Start your Free Trial

What is Opiant Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Opiant Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Sep. 2022 was 0.34.

Opiant Pharmaceuticals's long-term debt to total assets ratio increased from Sep. 2021 (0.28) to Sep. 2022 (0.34). It may suggest that Opiant Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Opiant Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Opiant Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opiant Pharmaceuticals LT-Debt-to-Total-Asset Chart

Opiant Pharmaceuticals Annual Data

Trend

Jul12

Jul13

Jul14

Jul15

Jul16

Jul17

Dec18

Dec19

Dec20

Dec21

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.31

0.24

Opiant Pharmaceuticals Quarterly Data
	Oct17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.28	0.24	0.24	0.29	0.34

Opiant Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Opiant Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

LT Debt to Total Assets (A: Dec. 2021 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2021 )	/	Total Assets (A: Dec. 2021 )
	=	16.742	/	70.428
	=	0.24

Opiant Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2022 is calculated as

LT Debt to Total Assets (Q: Sep. 2022 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2022 )	/	Total Assets (Q: Sep. 2022 )
	=	14.408	/	41.95
	=

Opiant Pharmaceuticals (NAS:OPNT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Opiant Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Opiant Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Opiant Pharmaceuticals (Opiant Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opiant Pharmaceuticals Inc (NAS:OPNT) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

233 Wilshire Boulevard, Suite 280, Santa Monica, CA, USA, 90401

Website

https://www.opiant.com

Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.

Executives

David D O'toole	officer: Chief Financial Officer	1640 MARENGO STREET, LOS ANGELES CA 90033
Ellison Mark Jason Heath	other: UK Managing Director	C/O OPIANT PHARMACEUTICALS, INC., 201 SANTA MONICA BLVD., SUITE 500, SANTA MONICA CA 90401
Roger Crystal	director, 10 percent owner, officer: Chief Executive Officer	445 PARK AVE, 10TH FL., NEW YORK NY 10022
Phil Skolnick	officer: Chief Scientific Officer	C/O DOV PHARMACEUTICAL, INC., 433 HACKENSACK AVENUE, HACKENSACK NJ 07601
Brian Gorman	other: General Counsel	233 WILSHIRE BLVD, SUITE 280, SANTA MONICA CA 90401
Matthew R. Ruth	officer: Chief Commercial Officer	233 WILSHIRE BLVD., SUITE 280, SANTA MONICA CA 90401
Michael Sinclair	director, 10 percent owner, officer: Executive Chairman	86 GLOUCESTER PLACE, LONDON XX W1U6HP
Craig A Collard	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Ann L. Macdougall	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Thomas T. Thomas	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Masuoka K. Lorianne	director	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Gabrielle Alison Silver	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Rahsaan Thompson	other: General Counsel	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Aziz Mottiwala	officer: Chief Commercial Officer	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Richard J Daly	director	355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134